{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:10:50Z","timestamp":1753891850791,"version":"3.41.2"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>A 73-year-old male with a history of multiple myeloma presented with progressively worsening left shoulder pain that was unresponsive to conservative management. Following comprehensive diagnostic procedures, including imaging and genetic testing, he was diagnosed with IgG lambda-type multiple myeloma, complicated by the development of myelomatous pleural effusion (MPE). The patient\u2019s treatment regimen consisted of the PDD chemotherapy combination, including Bortezomib, Doxorubicin, and Dexamethasone, alongside adjunctive therapies aimed at controlling the pleural effusion. Post-treatment evaluation revealed resolution of the pleural effusion, with no detectable myeloma cells in the pleural fluid. This case illustrates the clinical utility of combining chemotherapy with supportive treatments for the effective management of MPE in multiple myeloma patients. The patient\u2019s positive response highlights the significance of tailoring therapeutic approaches to the individual, emphasizing the role of personalized care in improving clinical outcomes in similar complex cases of MPE.<\/jats:p>","DOI":"10.3389\/fonc.2025.1554956","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T05:22:25Z","timestamp":1750396945000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Unveiling the role of genetic abnormalities in myelomatous pleural effusion: a case of IgG lambda-type multiple myeloma"],"prefix":"10.3389","volume":"15","author":[{"given":"Shuangyan","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lanfang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinjuan","family":"Mo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daoyin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102284","article-title":"Roadmap to cure multiple myeloma","volume":"100","author":"Rodriguez-Otero","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"B2","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13840","article-title":"Treatment horizon in multiple myeloma","volume":"109","author":"Soekojo","year":"2022","journal-title":"Eur J Haematology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"15330338221132370","DOI":"10.1177\/15330338221132370","article-title":"Clinical characteristics and prognosis of multiple myeloma with myelomatous pleural effusion: A retrospective single-center study","volume":"21","author":"Gao","year":"2022","journal-title":"Technol Cancer Res Treat"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1378\/chest.105.2.622","article-title":"Pleural effusion in multiple myeloma","volume":"105","author":"Rodr\u00edguez","year":"1994","journal-title":"Chest"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2147\/ijgm.s300337","article-title":"Clinical characteristics and risk factors for pleural effusion in patients with multiple myeloma","volume":"14","author":"Kang","year":"2021","journal-title":"IJGM"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/medicina55080490","article-title":"Malignant pleural effusion and its current management: A review","volume":"55","author":"Skok","year":"2019","journal-title":"Medicina"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3779\/10.3779\/j.issn.1009-3419.2021.101.24","article-title":"Progress of liquid biopsy in the diagnosis and treatment of lung cancer with Malignant pleural effusion","volume":"24","author":"Zeng","year":"2021","journal-title":"Chin J Lung Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.6004\/jnccn.2022.0002","article-title":"NCCN guidelines\u00ae Insights: multiple myeloma, version 3.2022","volume":"20","author":"Callander","year":"2022","journal-title":"J Natl Compr Cancer Network"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: A unique Malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-021-00633-5","article-title":"MRD assessment in multiple myeloma: progress and challenges","volume":"16","author":"Bertamini","year":"2021","journal-title":"Curr Hematol Malig Rep"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016170","article-title":"MRD in multiple myeloma: does CR really matter","volume":"140","author":"Paiva","year":"2022","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13194867","article-title":"Treatment strategy for multiple myeloma to improve immunological environment and maintain MRD negativity","volume":"13","author":"Suzuki","year":"2021","journal-title":"Cancers"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-022-03353-5","article-title":"Multiple myeloma with high-risk cytogenetics and its treatment approach","volume":"115","author":"Hanamura","year":"2022","journal-title":"Int J Hematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30756-7","article-title":"Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30020179","article-title":"Relapsed\/refractory multiple myeloma: A review of available therapies and clinical scenarios encountered in myeloma relapse","volume":"30","author":"Bhatt","year":"2023","journal-title":"Curr Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13148-019-0669-2","article-title":"Epigenetic silencing of miR-340-5p in multiple myeloma: mechanisms and prognostic impact","volume":"11","author":"Li","year":"2019","journal-title":"Clin Epigenet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.894279","article-title":"Novel myeloma patient-derived xenograft models unveil the potency of anlotinib to overcome bortezomib resistance","volume":"12","author":"Yue","year":"2022","journal-title":"Front Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018025106","article-title":"p53 regulates CD46 expression and measles virus infection in myeloma cells","volume":"2","author":"Lok","year":"2018","journal-title":"Blood Adv"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2147\/ijn.s102020","article-title":"Polyacrylate\/nanosilica causes pleural and pericardial effusion, and pulmonary fibrosis and granuloma in rats similar to those observed in exposed workers. International journal of nanomedicine","volume":"11","author":"Song","year":"2016","journal-title":"IJN"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.rce.2017.11.002","article-title":"Derrame pleural en el mieloma m\u00faltiple","volume":"218","author":"Porcel","year":"2018","journal-title":"Rev Cl\u00ednica Espa\u00f1ola"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-07-635383","article-title":"How I treat extramedullary myeloma","volume":"127","author":"Touzeau","year":"2016","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1159\/000477793","article-title":"Pleural effusion in multiple myeloma: characteristics and practice patterns","volume":"138","author":"Byun","year":"2017","journal-title":"Acta Haematol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.clml.2018.12.003","article-title":"Clinicopathological profile of myelomatous pleural effusion: single-center real-world experience and review of literature","volume":"19","author":"Yanamandra","year":"2019","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.55.4733","article-title":"Pleural effusion in multiple myeloma","volume":"55","author":"Wang","year":"2016","journal-title":"Intern Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e01333","DOI":"10.1002\/rcr2.1333","article-title":"Utilizing medical thoracoscopy for the diagnosis of myelomatous pleural effusion: 2 case reports","volume":"12","author":"Ng","year":"2024","journal-title":"Respirology Case Rep"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-015-0589-z","article-title":"Flow cytometry in diagnosis of myelomatous pleural effusion: A case report","volume":"32","author":"Arora","year":"2015","journal-title":"Indian J Hematol Blood Transfus"},{"key":"B28","doi-asserted-by":"publisher","first-page":"32","DOI":"10.25259\/cmas_02_03_2021","article-title":"Approach to diagnostic cytopathology of serous effusions","volume":"18","author":"Shidham","year":"2021","journal-title":"Cytojournal"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1554956\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T05:22:28Z","timestamp":1750396948000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1554956\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":28,"alternative-id":["10.3389\/fonc.2025.1554956"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1554956","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2025,6,20]]},"article-number":"1554956"}}